<h4>Objective</h4>Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 (SGLT-2) inhibitors reduce glycaemia and weight and improve insulin resistance (IR) <i>via</i> different mechanisms. Here, SLC5A2 is linked to Insulin resistance.